NRx Pharmaceuticals, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 16 Jan 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Change of auditor (8-K Item 4.01)
The company reported a change of its independent auditor in a Form 8-K (Item 4.01) filed on 26 Nov 2025. Auditor changes are often routine (rotation, cost, mergers), but can follow disagreements over accounting.
More details →NRx Pharmaceuticals, Inc. — Overview & Financial Snapshot
NRx Pharmaceuticals, Inc. (NasdaqCM: NRXP) is a Healthcare company, ranked #6,755 of 6,774 companies globally and #3,984 of 4,000 in United States on PositoAI, with a Positivity Score of -325,870. Its market capitalisation is ₹980.81 Cr ($103.91M), P/E ratio is -4.1 and P/B ratio is -611.23. It currently has 1 active red flag (PosiRed) and 1 yellow flag (PosiYellow, 2/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →